BPC-157 Dosage: Dosing, and What It Means for Lean Mass

BPC 157 dosage is the most searched question about this peptide and the least answerable one, because every published efficacy figure comes from rats. Nothing in the human literature has established a dose, a schedule or a route. The numbers that circulate in lifting forums were not derived from a trial in people. They were derived from arithmetic performed on animal data, then repeated until repetition made them sound official.

That gap matters here more than it would on a general health site. Lifters look this compound up for reasons that are body composition adjacent: an elbow that flares whenever volume climbs, a hamstring that keeps grabbing, six months of interrupted training that later show up as lost lean mass. The dosing question is really a question about whether the interruption can be shortened. Answering it honestly starts with admitting what the numbers describe.

Where the quoted figures actually originate

The efficacy literature on this pentadecapeptide is overwhelmingly rat work and cell culture work, much of it produced by a small number of research groups. Those experiments were designed to test whether a healing effect existed at all in a controlled injury, not to find a human dose. Animals were given body weight scaled amounts, usually in the microgram or nanogram per kilogram range, for a window matched to the injury being studied.

When those figures reach a forum, two conversions happen. The first is allometric scaling, a rough convention for translating animal doses across species by body size and metabolic rate. The second is rounding to something convenient for a reconstituted vial. Neither step is evidence. Allometric scaling is a starting assumption used to design a first human study, and the point of running that study is that the assumption is frequently wrong.

BPC 157 dosage in the animal work: what was actually specified

Read the source material and the specification is narrower than the forum version suggests. The studies specify an animal, an injury model, a route, a body weight scaled amount and a duration tied to how long that injury takes to resolve. They do not specify anything about training, body composition or an uninjured person.

The bottom two rows are the ones worth sitting with. A registered trial is not a result. NCT02637284 was a Phase 1 study of safety and pharmacokinetics in 42 participants with status listed as unknown, and pharmacokinetics is precisely the work that would let anyone speak about human dosing with a straight face. Until that reads out, dose talk in people is extrapolation wearing a lab coat.

Route changes the question more than the number does

Rat experiments have used intraperitoneal injection, intragastric delivery and drinking water, and reports of effect exist across those routes. That is unusual, and it is one of the more interesting features of the animal literature, because peptides of this size are not generally expected to survive digestion intact and reach tissue in useful amounts.

It also complicates every conversion. A quantity that produced an effect when placed directly into a rat's abdominal cavity is not the same quantity that would matter taken orally by a human, and the ratio between them is not known. Anyone quoting one number for both routes is quoting a number that cannot be right in both cases.

There is a second wrinkle that lifters in particular should notice. Some of the rat work applied the peptide locally, at or near the injured tendon, rather than systemically. A local effect at a repair site and a systemic effect measured somewhere else are different claims with different implications, and forum dosing charts flatten that distinction completely.

Capsules and oral solutions sold to consumers add a further problem. There is no marketing authorisation from the FDA, the EMA or the MHRA, so nothing enforces what is in the container. Content, purity and sterility rest entirely on the seller's own paperwork, and a certificate of analysis usually describes one batch rather than the vial you hold.

There is no dose for lean mass, because there is no lean mass endpoint

This is the part that gets skipped. Across the animal work, the outcomes measured were tendon and ligament healing, muscle crush injury recovery, gut lesion resolution and blood vessel formation. Nobody measured cross sectional area in a healthy animal. Nobody measured body composition. Nobody measured strength gained through training.

BPC-157 is not anabolic in any sense a lifter uses the word. It has no established action on the myostatin pathway, it is not described as stimulating muscle protein synthesis, and there is no hypertrophy or performance dataset in humans to argue about. Asking what dose builds lean mass is asking a question the literature has never posed, and no arithmetic on rat data will produce an answer to it.

The plausible connection to body composition is indirect and should be stated as the hypothesis it is: if connective tissue recovers faster, training continues, and training is what drives lean mass. That chain has never been tested end to end in a person. It is a reason the research is interesting, not a reason to treat a vial as a physique tool.

What the registered human trials could settle, and when

Human trials do exist and are registered, though none has published efficacy results. NCT07437547 is a Phase 2 study in 120 participants with acute hamstring strain, listed as recruiting. NCT07803250 is a Phase 1 study in 30 participants looking at rotator cuff repair recovery, listed as not yet recruiting.

Both are injury trials, which tells you where the serious interest sits: repair, not growth. If they report, they will produce the first human evidence about whether an effect exists and at what exposure. Neither is designed to answer anything about lean mass, and it would be a mistake to expect that from them.

Related reading on this compound: whether cycling applies here, what is known about side effects, why before and after images do not settle it.

Reading the dosing conversation without being misled

A few habits make the noise easier to filter. Ask which organism a number came from, because a figure with no species attached has usually lost its origin. Ask whether the outcome measured is the outcome you care about, since a healed rat tendon and a bigger human quadriceps are not the same claim. Notice when a schedule is presented with unusual precision, because precision that exceeds the underlying evidence is a marketing signal rather than a scientific one.

It also helps to separate two questions that get merged. One is whether the compound does anything in a human at any exposure, which is an efficacy question that the registered trials were built to address. The other is how much of it a person would need, which is a pharmacokinetic and dose response question. The second cannot be answered before the first, and treating a confident dosing chart as though both had been settled inverts the order in which evidence actually accumulates.

And notice the regulatory position, which is not a technicality. This is sold as a research chemical. In sport it falls under the non approved substances category, which means a tested athlete carries a sanction risk that no dosing discussion changes.